Cerebrolysin – Neuropeptide Research Mixture

Product Overview

Cerebrolysin is a standardized neuropeptide preparation derived from enzymatic hydrolysis of purified porcine (pig) brain proteins. Unlike discrete synthetic peptides with defined sequences, Cerebrolysin is a complex mixture of low-molecular-weight peptides (approximately 25%) and free amino acids (approximately 75%). The peptides in Cerebrolysin are no larger than 10,000 daltons and include bioactive fragments with neurotrophic activity similar to endogenous growth factors.

First developed in 1949 in Innsbruck, Cerebrolysin has been used for decades in clinical research, primarily in Europe and Asia, for studies on stroke, traumatic brain injury, and cognitive disorders. It is currently approved in more than 50 countries worldwide for neurological research applications.

⚠️ Critical Research Context: Cerebrolysin is not approved by the FDA for any human use in the United States. As a proprietary porcine brain extract with no single defined active pharmaceutical ingredient, it does not fit standard regulatory frameworks and is not available through licensed US pharmaceutical channels. The foundational preclinical evidence supporting Cerebrolysin’s mechanisms has been subject to image integrity challenges in recent years.

Composition and Mechanism of Action

Molecular Composition

Cerebrolysin is a defined mixture:

The proprietary manufacturing process ensures batch-to-batch consistency and removes larger peptides that may have antigenic potential.

Proposed Mechanisms

Preclinical research has identified several mechanisms of action:

• Neurotrophic Factor Mimicry: Contains peptides with activity similar to endogenous neurotrophic factors, enhancing neuronal survival and growth

• BDNF Modulation: Stimulates synthesis of brain-derived neurotrophic factor, which supports neuroplasticity

• Anti-Inflammatory Effects: Suppresses neuroinflammation and reduces pro-inflammatory mediators

• Apoptosis Inhibition: Reduces programmed cell death in injury models

• Blood-Brain Barrier Support: Increases glucose transport molecules at the BBB, supporting neuronal energy balance

• Neurogenesis & Synaptogenesis: Promotes new neuron formation and synaptic connections in research models

Key Research Applications:

• Ischemic stroke and neurorehabilitation models

• Traumatic brain injury studies

• Neurodegenerative disease research (Alzheimer’s, vascular dementia)

• Cognitive function and neuroplasticity investigations

• Neuroprotection and neurorestoration studies

Research Background

Preclinical Research

Animal models have demonstrated Cerebrolysin’s effects on:

• Reduced infarct volume and edema in cerebral ischemia models

• Improved learning and memory in aged and cognitively impaired animals

• Activation of the CREB/PGC-1α pathway, suppressing neuroinflammation

• Upregulation of BDNF and other neurotrophic factors essential for repair

Clinical Research Landscape

Approved Indications (International):

• Ischemic and hemorrhagic stroke (post-acute rehabilitation)

• Craniocerebral trauma and traumatic brain injury

• Vascular and Alzheimer’s dementia

• Organic brain disorders and neurodegenerative conditions

Recent TBI Cohort Study (2025):
A prospective single-blind study with 340 patients reported significantly greater improvement in Coma Recovery Scale-Revised scores at discharge (20.3 ± 2.7 vs. 16.4 ± 2.1; p=0.013), higher Barthel Index scores, lower modified Rankin Scale scores, and improved 6-month survival (59.4% vs. 27.8%; p<0.001) in the Cerebrolysin group.

Psychiatric Research Applications:
A 2025 review identified limited but suggestive research on Cerebrolysin as an adjunct in:

• Reducing neuroleptic side effects in psychosis

• Improving cognitive function in schizophrenia (when combined with risperidone)

• Treating depression in geriatric populations

• Reducing autistic features in pervasive developmental disorders

Critical Safety & Evidentiary Concerns

2023 Cochrane Review Findings:

• Pooling 7 RCTs with 1,773 participants found no evidence of benefit on all-cause death in acute ischemic stroke

• Statistically significant increase in non-fatal serious adverse events (RR 2.39)

Image Integrity Concerns (2024):
A dossier documented questionable images in eight foundational laboratory studies on Cerebrolysin conducted at the University of California San Diego, including a 2014 study in BMC Neuroscience and a 2016 study in Neurotoxicity Research. Ever Pharma, the manufacturer, stated these studies “played no crucial role in the clinical development of Cerebrolysin” but pledged to review the data.

Overall Evidence Quality:

• Industry-sponsored RCTs show positive results

• Independent Cochrane reviews consistently rate the evidence as low to very low certainty

• Some positive studies have been small, non-randomized, or lacking control groups

The “Gray Zone” Regulatory Status

Under U.S. federal law, drugs for human use must be FDA-approved or administered within a clinical trial. Cerebrolysin does not meet criteria for lawful compounding under Sections 503A or 503B, and distribution for human use is unlawful. Products sold as “research grade” are not legal for human use.

Product Specifications

Quality Assurance

Every batch undergoes rigorous analytical testing:

Certificate of Analysis (COA) available upon request.

Storage & Handling Guidelines

Storage Conditions:

• Lyophilized/Liquid (Long-term): -20°C, protected from light, sealed

• Liquid (Short-term): Room temperature (≤25°C) for immediate use; protect from light

• Do Not Freeze after reconstitution if stored in liquid form; avoid repeated freeze-thaw cycles

Handling Notes:

• Cerebrolysin is incompatible with solutions that change pH outside 5.0–8.0 and with lipid-containing solutions

• The solution should be used immediately after opening the ampoule/vial

Note: Cerebrolysin is a complex biological mixture. Stability, bioactivity, and batch-to-batch consistency can vary. Researchers should evaluate suitability for their specific experimental model.

Important Notice

⚠️ FOR RESEARCH USE ONLY

This product is not intended for human consumption, diagnostic use, therapeutic application, or clinical administration. Cerebrolysin is a research-grade mixture intended exclusively for in-vitro and laboratory research purposes.

• Not approved by the FDA for human use in the United States

• Not a dietary supplement, food additive, or pharmaceutical for over-the-counter purchase

• Distribution for human use outside approved clinical trials is unlawful under U.S. federal law

• Lack of single defined active ingredient makes regulatory approval pathway uncertain

• Evidence quality from independent reviews is low to very low; foundational preclinical data subject to image integrity concerns

• Intended solely for qualified researchers and scientific institutions

By purchasing this product, you confirm that you are a licensed researcher or laboratory professional and agree to use this compound in compliance with all applicable local, national, and international regulations.

Why Choose PeptidesUnit.com?

Order Now

Cerebrolysin Neuropeptide Mixture – ≥95% Purity
Available for immediate shipment

🛒 BUY NOW at PeptidesUnit.com

For bulk orders (10+ units), custom peptide synthesis, or wholesale inquiries, please contact our sales team at sales@peptidesunit.com.